Evidence map›Paper›PMID 38148377›Full record

ArticleBritish journal of cancer2024

PTEN-restoration abrogates brain colonisation and perivascular niche invasion by melanoma cells.

Sarah Wang, Caroline P Riedstra, Yu Zhang, Swetha Anandh, Andrew C Dudley

Open access · greenAbstract read
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. The Roles of PTEN in Melanoma Suppression.Pigment cell & melanoma research · 2025
    Review
  4. Molecular Underpinnings of Brain Metastases.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarah WangDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, VA, 22908, USA.ORCID http://orcid.org/0000-0002-2934-1410
Caroline P RiedstraDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, VA, 22908, USA.
Yu ZhangDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, VA, 22908, USA.
Swetha AnandhDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, VA, 22908, USA.
Andrew C DudleyDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, VA, 22908, USA. acd2g@virginia.edu.ORCID http://orcid.org/0000-0002-2663-1949
University of Virginia · USUniversity of Virginia Cancer Center

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
Targeting the vasculature to enhance anti-tumor immunityR01CA177875 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Andrew Carl Dudley · 2014 to 2026
$4.5M
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin MatricesR01CA258451 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUDLEY, ANDREW CARL, PECOT, CHAD V · 2021 to 2025
$2.9M
Mechanisms of perivascular melanoma dispersal and survival in the brainF30CA268842 · NCI · UNIVERSITY OF VIRGINIA · PI WANG, SARAH C · 2022 to 2025
$180k
NCI NIH HHS F30 CA268842NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA177875NCI NIH HHS T32 CA009109NIGMS NIH HHS T32 GM007267
6 · The paper itself

Abstract

backgroundMelanoma brain metastases (MBM) continue to be a significant clinical problem with limited treatment options. Highly invasive melanoma cells migrate along the vasculature and perivascular cells may contribute to residual disease and recurrence. PTEN loss and hyperactivation of AKT occur in MBM; however, a role for PTEN/AKT in perivascular invasion has not been described.

methodsWe used in vivo intracranial injections of murine melanoma and bulk RNA sequencing of melanoma cells co-cultured with brain endothelial cells (brECs) to investigate brain colonisation and perivascular invasion.

resultsWe found that PTEN-null melanoma cells were highly efficient at colonising the perivascular niche relative to PTEN-expressing counterparts. PTEN re-expression (PTEN-RE) in melanoma cells significantly reduced brain colonisation and migration along the vasculature. We hypothesised this phenotype was mediated through vascular-induced TGFβ secretion, which drives AKT phosphorylation. Disabling TGFβ signalling in melanoma cells reduced colonisation and perivascular invasion; however, the introduction of constitutively active myristolated-AKT (myrAKT) restored overall tumour size but not perivascular invasion.

conclusionsPTEN loss facilitates perivascular brain colonisation and invasion of melanoma. TGFβ-AKT signalling partially contributes to this phenotype, but further studies are needed to determine the complementary mechanisms that enable melanoma cells to both survive and spread along the brain vasculature.

Indexed as

MelanomaProto-Oncogene Proteins c-aktAnimalsBrainCell Line, TumorCell ProliferationEndothelial CellsHumansMicePTEN PhosphohydrolaseTransforming Growth Factor betaProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanPten protein, mouseTransforming Growth Factor beta

Identifiers

PMID38148377
PMCPMC10876963
OpenAlexW4390233698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.